logo
Share SHARE
FONT-SIZE Plus   Neg

Forest Labs., Gedeon Report Results From 2 Phase III Trials Of Cariprazine

Forest Laboratories, Inc. (FRX) and Gedeon Richter Plc announced positive top-line results in 2 Phase III clinical trials of cariprazine (RGH-188) for treating acute exacerbation of schizophrenia.

For the primary endpoint in each study, the Positive And Negative Syndrome Scale, the data showed that cariprazine-treated patients experienced significant symptom improvement compared to placebo-treated patients.

Besides, all doses showed statistically significant separation from placebo starting at week 2 and at each subsequent time point with the higher dose showing separation as early as week 1 of treatment. Further analyses of the data in each study will be completed in the coming weeks.

Forest Labs noted that the results of these 2 studies were consistent with the results of the previously completed placebo-controlled Phase IIb fixed-dose study in this population.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Shares of Nokia Corp. were gaining around 6 percent in mid-morning trading in Finland after the network equipment maker reported Thursday narrower loss in its first quarter. The company also reiterated its fiscal 2017 outlook for total cost savings. CEO Rajeev Suri said, "Overall, given Nokia's performance in the first quarter, I am optimistic about the year ahead, even if cautiously so." Aerospace and defense major Airbus Group SE reported Thursday higher profit and revenues in its first quarter with growth in all segments, except defence. Adjusted EBIT, a key earnings metric, meanwhile declined from last year. Looking ahead, for fiscal 2017, Airbus continues to expect mid-single-digit percentage growth in adjusted earnings per share and adjusted EBIT. Shares of AstraZeneca Plc were declining in the morning trading in London after the British drug giant reported Thursday weak profit and revenues in its first quarter, as product sales were hurt mainly by the residual impact of the US Crestor patent expiry. Core profit, however, increased with improved cost control. Further, the company confirmed its financial guidance for 2017.
comments powered by Disqus
Follow RTT